RNS Number : 8970B
23 April 2012
For immediate release 23 April 2012
("Abcam" or "the Company")
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, has today been notified that on 23 April 2012, Jonathan Milner, a Director of the Company, transferred 169,000 ordinary shares of 0.2 pence each in the Company ("Ordinary Shares") for nil consideration to a charitable trust. On the same day, the charitable trust sold 85,000 Ordinary Shares at a price of 356.785p per Ordinary Share.
Following these transactions, Dr Milner's total beneficial interest in the Company is 27,929,378 Ordinary Shares representing approximately 15.2% of the Company's issued share capital.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Numis Securities (Financial Adviser, Nomad and
Joint Broker) + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Peel Hunt (Joint Broker) + 44 (0) 20 7418 8900
Andy Crossley - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China), allowing it to serve a global customer base in over 85 countries. Abcam employs over 340 staff across its six operating companies.
Abcam now has an online catalogue of over 90,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the world's leading life science tools company.
This information is provided by RNS
The company news service from the London Stock Exchange